

Evaluation of a molecular point-of-care testing for viral
intravenous antibiotic duration in hospitalized adults with
infection: a randomized clinical trial

Clinical Microbiology and Infection

25, 1415-1421

DOI: [10.1016/j.cmi.2019.06.012](https://doi.org/10.1016/j.cmi.2019.06.012)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Testing for viral infections in severe lower respiratory tract infections; the unpredictable effects of diagnostic certainty. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1302-1303.	2.8	2
2	Antimicrobial Stewardship and Implementation of Rapid Multiplex Respiratory Diagnostics: Is There Method in the Madness?. <i>Clinical Infectious Diseases</i> , 2020, 71, 1690-1692.	2.9	3
4	Rapid detection of respiratory organisms with FilmArray respiratory panel and its impact on clinical decisions in Shanghai, China, 2016-2018. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 142-149.	1.5	17
5	Viral pneumonia in China: from surveillance to response. <i>Lancet Public Health</i> , The, 2020, 5, e633-e634.	4.7	6
6	Multiplex Tests for Respiratory Tract Infections: The Direct Utility of the FilmArray Respiratory Panel in Emergency Department. <i>Canadian Respiratory Journal</i> , 2020, 2020, 1-8.	0.8	9
7	Physicians' prediction for the assessment of atypical pathogens in respiratory tract infections. <i>Journal of General and Family Medicine</i> , 2020, 21, 226-234.	0.3	2
8	Impact of comprehensive molecular testing to reduce antibiotic use in community-acquired pneumonia (RADICAP): a randomised, controlled, phase IV clinical trial protocol. <i>BMJ Open</i> , 2020, 10, e038957.	0.8	1
9	Rapid and Point-of-Care Testing in Respiratory Tract Infections: An Antibiotic Guardian?. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 401-417.	2.5	17
10	Multiplex PCR implementation as point-of-care testing in a French emergency department. <i>Journal of Hospital Infection</i> , 2020, 105, 337-338.	1.4	10
11	Impact of BioFire FilmArray respiratory panel results on antibiotic days of therapy in different clinical settings. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2021, 1, .	0.2	6
12	Molecular Diagnosis of Pneumonia (Including Multiplex Panels). <i>Clinical Chemistry</i> , 2021, 68, 59-68.	1.5	5
13	Rapid Point-of-Care Assays. , 2021, , 45-51.		0
14	Anti-infectious treatment duration: The SPILF and GPIP French guidelines and recommendations. <i>Infectious Diseases Now</i> , 2021, 51, 114-139.	0.7	21
15	Nucleic Acid-based Testing for Noninfluenza Viral Pathogens in Adults with Suspected Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1070-1087.	2.5	23
17	An evaluation of the Unyvero pneumonia system for rapid detection of microorganisms and resistance markers of lower respiratory infections—a multicenter prospective study on ICU patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2113-2121.	1.3	5
18	BioFire® FilmArray® Pneumonia Panel for Severe Lower Respiratory Tract Infections: Subgroup Analysis of a Randomized Clinical Trial. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1437-1449.	1.8	18
21	Virulence Factors and Azole-Resistant Mechanism of <i>Candida Tropicalis</i> Isolated from Candidemia. <i>Mycopathologia</i> , 2021, 186, 847-856.	1.3	6
22	C-reactive protein or procalcitonin combined with rhinorrhea for discrimination of viral from bacterial infections in hospitalized adults in non-intensive care units with lower respiratory tract infections. <i>BMC Pulmonary Medicine</i> , 2021, 21, 308.	0.8	3

#	ARTICLE	IF	CITATIONS
23	Added value of rapid respiratory syndromic testing at point of care versus central laboratory testing: a controlled clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, iii20-iii27.	1.3	14
24	Point of care testing for infectious disease: ownership and quality. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, iii28-iii32.	1.3	6
25	Do point-of-care tests (POCTs) offer a new paradigm for the management of patients with influenza?. <i>Eurosurveillance</i> , 2020, 25, .	3.9	7
26	Point-of-care tests for influenza A and B viruses and RSV in emergency departments – indications, impact on patient management and possible gains by syndromic respiratory testing, Capital Region, Denmark, 2018. <i>Eurosurveillance</i> , 2020, 25, .	3.9	8
27	Evaluation of Panbio rapid antigen test for SARS-CoV-2 in symptomatic patients and their contacts: a multicenter study. <i>International Journal of Infectious Diseases</i> , 2021, 113, 218-224.	1.5	16
28	Respiratory viral infections in pragmatically selected adults in intensive care units. <i>Scientific Reports</i> , 2021, 11, 20058.	1.6	5
29	Molecular diagnostic methods for pneumonia: how can they be applied in practice?. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 118-125.	1.3	5
30	Impact of multiplexed respiratory viral panels on infection control measures and antimicrobial stewardship: a review of the literature. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 187-202.	1.3	5
31	Evaluation of Molecular Point-of-Care Testing for Respiratory Pathogens in Children With Respiratory Infections: A Retrospective Case-Control Study. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 778808.	1.8	3
33	Viral Respiratory Infections: New Tools for a Rapid Diagnosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 747-758.	0.8	4
34	Effect of Gram Stain-Guided Initial Antibiotic Therapy on Clinical Response in Patients With Ventilator-Associated Pneumonia. <i>JAMA Network Open</i> , 2022, 5, e226136.	2.8	17
35	Rhinoviruses: molecular diversity and clinical characteristics. <i>International Journal of Infectious Diseases</i> , 2022, 118, 144-149.	1.5	1
36	Detection of bacteria via multiplex PCR in respiratory samples of critically ill COVID-19 patients with suspected HAP/VAP in the ICU. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 385-390.	1.0	11
37	Value of syndromic panels in the management of severe community-acquired pneumonia. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 15-20.	0.5	3
38	Urgent need for a rapid microbiological diagnosis in critically ill pneumonia. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 6-14.	0.5	2
39	Improving management and antimicrobial stewardship for bacterial and fungal infections in hospitalized patients with COVID-19. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612210957.	1.1	3
40	Development and evaluation of a multiplex quantitative polymerase chain reaction assay for detecting bacteria associated with lower respiratory tract infection. <i>International Journal of Infectious Diseases</i> , 2022, 122, 202-211.	1.5	2
41	Early identification and severity prediction of acute respiratory infection (ESAR): a study protocol for a randomized controlled trial. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	3

#	ARTICLE	IF	CITATIONS
42	Diagnostic des pneumonies aiguës communautaires aux urgences et distinction entre Étiologie virale ou bactérienne. Annales Francaises De Medecine D'Urgence, 2022, 12, 383-390.	0.0	0
44	Antimicrobial Overuse in COVID-19 “ Reasons to remain vigilant as we approach the winter “etwindemic”: Journal of Hospital Infection, 2022, , .	1.4	0
45	Rapid multiplex PCR for respiratory viruses reduces time to result and improves clinical care: Results of a systematic review and meta-analysis. Journal of Infection, 2023, 86, 462-475.	1.7	13